MX364679B - Multivalent pneumococcal polysaccharide-protein conjugate composition. - Google Patents
Multivalent pneumococcal polysaccharide-protein conjugate composition.Info
- Publication number
- MX364679B MX364679B MX2015007300A MX2015007300A MX364679B MX 364679 B MX364679 B MX 364679B MX 2015007300 A MX2015007300 A MX 2015007300A MX 2015007300 A MX2015007300 A MX 2015007300A MX 364679 B MX364679 B MX 364679B
- Authority
- MX
- Mexico
- Prior art keywords
- serotypes
- protein conjugate
- conjugate composition
- pneumococcal polysaccharide
- multivalent pneumococcal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Abstract
Disclosed is an immunogenic composition having 13 different polysaccharide-protein conjugates. Each conjugate contains a capsular polysaccharide which is prepared from different serotypes of streptococcus pneumonia conjugated to a carrier protein, in particular 12 serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and serotypes 2 or 9N. The immunogenic composition formulated as a vaccine having an aluminum-based adjuvant increases coverage against pneumococcal disease in infants and young children.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120143310A KR20140075196A (en) | 2012-12-11 | 2012-12-11 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
PCT/KR2013/011194 WO2014092377A1 (en) | 2012-12-11 | 2013-12-05 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015007300A MX2015007300A (en) | 2016-01-20 |
MX364679B true MX364679B (en) | 2019-05-03 |
Family
ID=50934608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015007300A MX364679B (en) | 2012-12-11 | 2013-12-05 | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9981029B2 (en) |
EP (1) | EP2932979B1 (en) |
JP (1) | JP2016503015A (en) |
KR (1) | KR20140075196A (en) |
CN (1) | CN104837505A (en) |
AU (1) | AU2013360596B2 (en) |
BR (1) | BR112015013560A8 (en) |
CA (1) | CA2896528C (en) |
ES (1) | ES2831375T3 (en) |
MX (1) | MX364679B (en) |
PH (1) | PH12015501269A1 (en) |
RU (1) | RU2606152C1 (en) |
WO (1) | WO2014092377A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102220506B1 (en) | 2005-04-08 | 2021-03-02 | 와이어쓰 엘엘씨 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
KR102149760B1 (en) | 2015-01-15 | 2020-08-31 | 화이자 인코포레이티드 | Immunogenic composition for use in pneumococcal vaccine |
SG11201708242YA (en) | 2015-05-04 | 2017-11-29 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
BR112017028130A2 (en) | 2015-06-23 | 2018-08-28 | Biological E Ltd | multivalent pneumococcal conjugate vaccine |
MY187472A (en) * | 2015-09-10 | 2021-09-23 | Inventprise Llc | Multivalent vlp conjugates |
CA3000201A1 (en) * | 2015-10-07 | 2017-04-13 | Boehringer Ingelheim Vetmedica, Inc. | Streptococcus suis polysacchari de-protein conjugate composition |
US10864261B2 (en) * | 2015-12-17 | 2020-12-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic vaccines against Streptococcus pneumoniae serotype 2 |
CN106075430A (en) * | 2016-06-30 | 2016-11-09 | 武汉博沃生物科技有限公司 | Multivalent pneumococcal ACYW135 meningococcus combined vaccine |
CN106075420A (en) * | 2016-06-30 | 2016-11-09 | 武汉博沃生物科技有限公司 | Multivalent pneumococcal Type B hemophilus influenza combined vaccine |
MX2019001342A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP2019529497A (en) | 2016-09-30 | 2019-10-17 | バイオロジカル イー リミテッド | Polyvalent pneumococcal vaccine composition comprising a polysaccharide-protein conjugate |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
US11197921B2 (en) | 2017-01-31 | 2021-12-14 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
SG11202005255PA (en) | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CN108079286B (en) * | 2018-01-19 | 2020-07-31 | 云南沃森生物技术股份有限公司 | 13-valent pneumococcal polysaccharide-protein conjugate composition and preparation method and application thereof |
CA3089007A1 (en) * | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2019152921A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP2021522213A (en) | 2018-04-18 | 2021-08-30 | エスケー バイオサイエンス カンパニー リミテッド | Streptococcus pneumoniae capsular polysaccharide and its immunogenic zygotes |
WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
JP7399934B2 (en) | 2018-07-04 | 2023-12-18 | バックスサイト・インコーポレイテッド | Improvement of immunogenic complexes |
MX2021007496A (en) | 2018-12-19 | 2021-08-05 | Merck Sharp & Dohme Llc | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof. |
EP3919076A1 (en) | 2020-06-02 | 2021-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH0832638B2 (en) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | Adjuvant formulation comprising submicron oil droplet emulsion |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
ES2231770T3 (en) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | NEW PLASMIDS FOR THE PRODUCTION OF CRM PROTEIN AND DIFTERIC TOXIN. |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
MXPA01003228A (en) | 1998-09-30 | 2003-06-24 | American Cyanamid Co | Mutant cholera holotoxin as an adjuvant. |
MY125387A (en) * | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
FR2806304B1 (en) | 2000-03-17 | 2002-05-10 | Aventis Pasteur | POLYSACCHARIDIC CONJUGATES OF PNEUMOCOCCUS FOR VACCINE USE AGAINST TETANUS AND DIPHTHERIA |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
AU2002227450B2 (en) | 2000-12-28 | 2008-02-28 | Wyeth | Recombinant protective protein from $I(streptococcus pneumoniae) |
EP2278013A1 (en) | 2001-04-16 | 2011-01-26 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
JP2005508143A (en) | 2001-06-07 | 2005-03-31 | ワイス・ホールデイングス・コーポレーシヨン | Mutated form of cholera holotoxin as an adjuvant |
CN1297316C (en) | 2001-06-07 | 2007-01-31 | 惠氏控股有限公司 | Mutant forms of cholera holotoxin as adjuvant |
US20060251675A1 (en) | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
JP4079925B2 (en) | 2004-08-09 | 2008-04-23 | Necアクセステクニカ株式会社 | transceiver |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
KR102220506B1 (en) * | 2005-04-08 | 2021-03-02 | 와이어쓰 엘엘씨 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN103083657B (en) | 2005-06-27 | 2016-06-08 | 葛兰素史密丝克莱恩生物有限公司 | Immunogenic composition |
KR101515078B1 (en) | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccines |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
ES2552366T3 (en) * | 2007-06-26 | 2015-11-27 | Glaxosmithkline Biologicals S.A. | Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae |
GB0714963D0 (en) * | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
WO2010125480A1 (en) | 2009-04-30 | 2010-11-04 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
CN101590224A (en) * | 2009-06-30 | 2009-12-02 | 广州精达医学科技有限公司 | High-efficiency 14-valent pneumococcal conjugate vaccine |
TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
PT2575870T (en) * | 2010-06-04 | 2017-02-10 | Wyeth Llc | Vaccine formulations |
MX2013006539A (en) | 2010-12-10 | 2013-07-22 | Merck Sharp & Dohme | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions. |
-
2012
- 2012-12-11 KR KR1020120143310A patent/KR20140075196A/en not_active IP Right Cessation
-
2013
- 2013-12-05 JP JP2015547844A patent/JP2016503015A/en active Pending
- 2013-12-05 MX MX2015007300A patent/MX364679B/en active IP Right Grant
- 2013-12-05 EP EP13862717.9A patent/EP2932979B1/en active Active
- 2013-12-05 AU AU2013360596A patent/AU2013360596B2/en active Active
- 2013-12-05 CA CA2896528A patent/CA2896528C/en active Active
- 2013-12-05 CN CN201380064974.XA patent/CN104837505A/en active Pending
- 2013-12-05 BR BR112015013560A patent/BR112015013560A8/en not_active Application Discontinuation
- 2013-12-05 ES ES13862717T patent/ES2831375T3/en active Active
- 2013-12-05 WO PCT/KR2013/011194 patent/WO2014092377A1/en active Application Filing
- 2013-12-05 RU RU2015121772A patent/RU2606152C1/en active
- 2013-12-05 US US14/651,021 patent/US9981029B2/en active Active
-
2015
- 2015-06-04 PH PH12015501269A patent/PH12015501269A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013360596A1 (en) | 2015-07-02 |
WO2014092377A1 (en) | 2014-06-19 |
BR112015013560A8 (en) | 2018-07-31 |
MX2015007300A (en) | 2016-01-20 |
RU2606152C1 (en) | 2017-01-10 |
EP2932979B1 (en) | 2020-10-21 |
EP2932979A1 (en) | 2015-10-21 |
KR20140075196A (en) | 2014-06-19 |
JP2016503015A (en) | 2016-02-01 |
CA2896528C (en) | 2019-03-19 |
AU2013360596B2 (en) | 2016-03-31 |
CA2896528A1 (en) | 2014-06-19 |
PH12015501269B1 (en) | 2016-02-01 |
CN104837505A (en) | 2015-08-12 |
US20160375118A1 (en) | 2016-12-29 |
PH12015501269A1 (en) | 2016-02-01 |
US9981029B2 (en) | 2018-05-29 |
ES2831375T3 (en) | 2021-06-08 |
EP2932979A4 (en) | 2016-06-01 |
BR112015013560A2 (en) | 2017-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501269A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
PH12015501270A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
AR116043A2 (en) | COMPOSITION OF CONJUGATED VACCINE OF POLYSACCHARIDE-PNEUMOCOCCAL PROTEIN 15-VALENT | |
PH12014502843B1 (en) | Polyvalent pneumococcal polysaccharide-protein conjugate composition | |
PH12019500240A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
MY145150A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
MX2013006539A (en) | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions. | |
MX2009006705A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition. | |
PH12019500238A1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
WO2011151760A3 (en) | Streptococcus pneumoniae vaccine formulations | |
MX336934B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition. | |
AR093161A1 (en) | COMPOSITION OF POLYACARIDO-PROTEIN PNEUMOCOCICES CONJUGATES MULTIVALENT | |
TH128171B (en) | Composition of 15-valent conjugate vaccine, pneumococcal polysaccharide-protein | |
TH160962B (en) | "Multivalent elements Nimococcus polysaccharides - conjugated proteins " | |
TH128171A (en) | Composition of 15-valent conjugate vaccine, pneumococcal polysaccharide-protein | |
TH108545B (en) | Mixture, multivalent, pneumococcal, polysaccharide-conjugate protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: SK BIOSCIENCE CO., LTD. |
|
HC | Change of company name or juridical status |
Owner name: BUSS AG |
|
GB | Transfer or rights |
Owner name: SK BIOSCIENCE CO., LTD. |
|
FG | Grant or registration |